Alexandria, Va. — On October 10 and 11, the Prevent Cancer Foundation® brought together experts and leaders in science, policy and practice at the Quantitative Imaging Workshop XVI: Lung Cancer, COPD and Cardiovascular Disease – On the Cusp of Transformation. The Workshop is a high-impact, multi-disciplinary forum for the advancement of quantitative CT imaging biomarkers. Attendees explore exciting new biomedical opportunities that this transformational technology enables.
The Foundation has convened this annual workshop since 2003, with a focus on high-resolution CT imaging data for lung cancer, COPD and cardiovascular disease. The Workshop provides a forum to exchange ideas on quantitative CT imaging for early disease management, as well as on policy and advocacy for responsible lung cancer, COPD and cardiovascular screening. This event emphasizes quality and consistency in screening.
Each year, this unique forum brings together leaders in lung cancer, COPD and cardiovascular disease early detection and treatment of early-stage disease, including oncologists, radiologists, photonics experts, federal policymakers and regulators, pharmaceutical professionals and patient advocates.
Andrew C. von Eschenbach, known for his work leading the National Lung Screening Trial, the first large-scale clinical trial for low-dose CT lung cancer screening, was honored at the Workshop with the James L. Mulshine, M.D. Leadership Award.
